Paradox Immunotherapeutics

Profile

Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating conditions with limited treatment options and high mortality. Backed by a team with a proven track record, including the design of an antibody that led to a $1.2B acquisition deal in 2021, Paradox uses a proprietary platform that requires only the native protein structure to develop antibodies that selectively deplete pathological proteins and currently has 3 new candidates ready to disrupt the protein misfolding industry.

paradox immunotherapeutics

Website

paradoximmuno.com

Contact


Event details

Date: June 16 - 19, 2025

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total